Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additional biosimilar candidates in Europe.

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient ...

A new NDA was submitted in January 2024, which the FDA did accept, and that was later converted into a priority review. An ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting ...